Bosulif

Chemical Namebosutinib
Dosage FormTablets (oral; 100mg, 500mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyPfizer Inc.
Approval Year2012

Indication

  • For the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Bosulif (bosutinib) Prescribing Information2012Pfizer Inc., New York, NY
Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network
Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2017Annals of Oncology